The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015
Open accessAbstract
) data for NA inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Furthermore, NA sequences from 13,484 influenza viruses were retrieved from public sequence databases and screened for amino acid substitutions (AAS) associated with reduced inhibition (RI) or highly reduced inhibition (HRI) by NAIs. Of the viruses tested by WHO CCs 93% were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.8% (n = 113) exhibited either RI or HRI by at least one of four NAIs. As in previous seasons, the most common NA AAS was H275Y in A(H1N1)pdm09 viruses, which confers HRI by oseltamivir and peramivir. Two A(H1N1)pdm09 viruses carried a rare NA AAS, S247R, shown in this study to confer RI/HRI by the four NAIs. The overall frequency of A(H1N1)pdm09 viruses containing NA AAS associated with RI/HRI was approximately 1.8% (125/6915), which is slightly higher than in the previous 2014-15 season (0.5%). Three B/Victoria-lineage viruses contained a new AAS, NA H134N, which conferred HRI by zanamivir and laninamivir, and borderline HRI by peramivir. A single B/Victoria-lineage virus harboured NA G104E, which was associated with HRI by all four NAIs. The overall frequency of RI/HRI phenotype among type B viruses was approximately 0.6% (43/7677), which is lower than that in the previous season. Overall, the vast majority (>99%) of the viruses tested by WHO CCs were susceptible to all four NAIs, showing normal inhibition (NI). Hence, NAIs remain the recommended antivirals for treatment of influenza virus infections. Nevertheless, our data indicate that it is prudent to continue drug susceptibility monitoring using both NAI assay and sequence analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garten, R. J., Davis, C. T., Russell, C. A., Shu, B., Lindstrom, S., Balish, A., Sessions, W. M., Xu, X., Skepner, E., Deyde, V., et al. (2009) · Science · doi:10.1126/science.1176225 · Cited by 2,499
Self-citationPotier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 815
Bright, R. A., Medina, M.-J., Xu, X., Perez-Oronoz, G., Wallis, T. R., Davis, X. M., Povinelli, L., Cox, N. J., & Klimov, A. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67338-2 · Cited by 725
Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance
Bloom, J. D., Gong, L. I., & Baltimore, D. (2010) · Science · doi:10.1126/science.1187816 · Cited by 649
Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
Dharan, N. J. (2009) · JAMA · doi:10.1001/jama.2009.294 · Cited by 527
Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., & Gubareva, L. V. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-08 · Cited by 480
Self-citationInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 390
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season
Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Opp, M., Paget, J., van de Kassteele, J., Hay, A. J., et al. (2009) · Emerging infectious diseases · doi:10.3201/eid1504.081280 · Cited by 362
Self-citationEmergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe
Lackenby, A., Hungnes, O., Dudman, S. G., Meijer, A., Paget, W. J., Hay, A. J., & Zambon, M. C. (2008) · Eurosurveillance · doi:10.2807/ese.13.05.08026-en · Cited by 318
Self-citationHurt, A. C., Ernest, J., Deng, Y.-M., Iannello, P., Besselaar, T. G., Birch, C., Buchy, P., Chittaganpitch, M., Chiu, S.-C., Dwyer, D., et al. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.03.003 · Cited by 277
Self-citation
Cited by
Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
Inhibition of sialidase activity as a therapeutic approach
Glanz, V. Y., Myasoedova, V. A., Grechko, A. V., & Orekhov, A. N. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s176220 · Cited by 59
Metadata
- Authors
- Hurt, A. C., Besselaar, T. G., Daniels, R. S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R. T. C., Lo, J., Maurer-Stroh, S., Nguyen, H. T., Pereyaslov, D., Rebelo-de-Andrade, H., Siqueira, M. M., Takashita, E., Tashiro, M., Tilmanis, D., Wang, D., Zhang, W., & Meijer, A.
- Venue
- Antiviral Research
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 132
- Pages
- 178-185
- ISSN
- 0166-3542 (ISSN-L)
- OpenAlex
- W1968256827
- Cited by
- 270
- References
- 36
- FWCI
- 39.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. https://app.cochat.ai/papers/10.1016/j.antiviral.2016.06.001
- The paper
- Hurt, A. C., Besselaar, T. G., Daniels, R. S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R. T. C., Lo, J., Maurer-Stroh, S., Nguyen, H. T., Pereyaslov, D., Rebelo-de-Andrade, H., Siqueira, M. M., Takashita, E., Tashiro, M., Tilmanis, D., Wang, D., . . . Meijer, A. (2016). Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Research. https://doi.org/10.1016/j.antiviral.2016.06.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
